Key Takeaways
- • Thermo Fisher Scientific announced the sale of its microbiology business to European private equity firm Astorg for over $1.1 billion, marking a significant divestiture in the life sciences sector.
- • Four law firms are steering the transaction, indicating a complex, multi-jurisdictional deal structure typical of large cross-border acquisitions.
- • The deal represents Astorg's expansion into the microbiology segment, a specialized niche within life sciences with recurring revenue characteristics attractive to PE investors.
- • The transaction was announced on Monday, April 27, 2026, and demonstrates ongoing consolidation activity in the life sciences and diagnostics market.
Summary
Thermo Fisher Scientific announced plans to divest its microbiology business to Astorg, a prominent European private equity firm, in a transaction valued at over $1.1 billion. The announcement came on Monday, April 27, 2026, and underscores the ongoing reshaping of the life sciences sector through strategic asset sales and PE-driven consolidation.
The microbiology business represents a focused operational unit within Thermo Fisher's broader portfolio, likely encompassing products, services, and intellectual property related to microbial analysis, testing, and diagnostics. By selling this business to Astorg, Thermo Fisher is executing a portfolio optimization strategy, potentially redirecting capital toward higher-priority growth areas or returning value to shareholders.
The transaction is being executed with the involvement of four law firms, signaling the complexity inherent in cross-border M&A activity between a U.S. public company and a European acquirer. These firms are managing legal due diligence, regulatory compliance, and transaction structuring across multiple jurisdictions. The scale of legal support reflects the need to navigate varying regulatory frameworks, particularly in healthcare and life sciences, where FDA, EMA, and other regulatory bodies may have oversight.
For Astorg, the acquisition adds a specialized asset to its portfolio with stable, recurring revenue characteristics typical of microbiology testing and diagnostics businesses. This deal aligns with broader PE trends of acquiring niche, mission-critical services within healthcare and life sciences where pricing power and customer stickiness remain high.
The microbiology business represents a focused operational unit within Thermo Fisher's broader portfolio, likely encompassing products, services, and intellectual property related to microbial analysis, testing, and diagnostics. By selling this business to Astorg, Thermo Fisher is executing a portfolio optimization strategy, potentially redirecting capital toward higher-priority growth areas or returning value to shareholders.
The transaction is being executed with the involvement of four law firms, signaling the complexity inherent in cross-border M&A activity between a U.S. public company and a European acquirer. These firms are managing legal due diligence, regulatory compliance, and transaction structuring across multiple jurisdictions. The scale of legal support reflects the need to navigate varying regulatory frameworks, particularly in healthcare and life sciences, where FDA, EMA, and other regulatory bodies may have oversight.
For Astorg, the acquisition adds a specialized asset to its portfolio with stable, recurring revenue characteristics typical of microbiology testing and diagnostics businesses. This deal aligns with broader PE trends of acquiring niche, mission-critical services within healthcare and life sciences where pricing power and customer stickiness remain high.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.